GITR/TNFRSF18 Antibody (DTA-1) - Chimeric - Azide and BSA Free

This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques.

This antibody has been used in various FACS analyses for diverse immuno-oncological applications, such as to delineate how membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF- beta signaling (Ansa-Addo et al, 2017), to suggest the therapeutic potential of TGF- beta -induced Tregs (iTregs) in treating autoimmune gastritis (Nguyen et al, 2014), and to demonstrate that costimulation with the ligand of GITR elicites dose-dependent enrichment for cells of lower TCR affinity in the Treg cell repertoire (Mahmud et al, 2014). This antibody has also been used in Western Blots to elucidate the mechanism of human T-cell leukemia virus type 1 (HTLV-1) in the development of neoplastic and inflammatory diseases (Satou et al, 2011), and in immunoprecipitation analysis to aid the investigation of the role of GITR in dominant immunological self-tolerance maintained by CD25+CD4+ regulatory T cells (Shimizu et al, 2002). In addition, the anti-tumour effects of this agonistic anti-GITR antibody have been demonstrated in various murine models (Scirka et al, 2017; Coe et al, 2010; Cohen et al. 2010; Hu et al, 2008; Ko et al, 2005).